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The 2009 pandemic caused by influenza A(H1N1) pdm09 virus resulted in more than 18 
500 deaths reported worldwide and global estimates that were 15-fold higher.1 In contrast to 
seasonal influenza epidemics, during which elderly persons have the highest risk for 
hospitalization and death, many critically ill patients during the 2009 H1N1 pandemic were 
young or middle-aged adults.2 Other notable riskfactors were morbid obesity and pregnancy, 
including the early postpartum period.2 The dominant feature of critical illness during the 
2009 H1N1 pandemic was severe acute respiratory distress syndrome (ARDS)that often 
developed very quicklyfollowing presentation to the hospital and frequently was associated 
with a long and protracted course and high mortality.2
Since 2009, H1N1pdm09 virus has continued to circulate and cause critical illness 
worldwide, but it has not predominated in the United States until this season, with a 
corresponding resurgence of influenza-related hospitalizations, critical illness, severe ARDS, 
and deaths. This year more than 60% of laboratory-confirmed influenza-associated 
hospitalizations and deaths reported in adults younger than 65 years to date have been 
attributed to H1N1.3,4 No significant antigenic changes in circulating H1N1pdm09 virus 
strains compared with vaccine strains have been detected since 2009. The relative effect on 
young and middle-aged adults might be partially due to their low influenza vaccine coverage 
and cross-reactive immunity to H1N1pdm09 virus that elderly individuals have acquired 
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from past exposure to antigenically related viruses. Based on lessons learned from the 2009 
H1N1 pandemic, we offer suggestions for the care and management of H1N1pdm09 patients 
at risk for critical illness during this influenza season.
Clinical Features
Although most persons with H1N1pdm09 virus infection will not develop critical illness, 
those who do often deteriorate rapidly. The typical presentation is influenza-like illness with 
sudden onset of fever, cough, rhinorrhea, and myalgia. Deterioration occurs after 
approximately 4 to 5 days and is characterized by hypoxemia, shock, and multiorgan 
dysfunction.2 Hemodynamic and oxygenation monitoring is recommended so that intubation 
and resuscitation can be instituted promptly. Of note, 60% of those requiring noninvasive 
ventilation progressed to endotracheal intubation.5
Patients with H1N1pdm09 who require intubation are at high risk of a rapidly progressive 
viral pneumonia and severe ARDS (Pao2/Fio2 <100). The pathogenesis of H1N1pdm09 
virus infection resultingin critical illness is primarily driven by an intense inflammatory (and 
sometimes hemorrhagic) host response in the lung to the virus (eFigure in the Supplement). 
The severity of ARDS is likely influenced by multiple factors, including H1N1pdm09 virus 
infection of the respiratory tract as the initiator, the host inflammatory response (which can 
be extremely variable), and possible secondary bacterial pneumonia. Although 
corticosteroids could theoretically ameliorate inflammation-induced injury, they are 
associated with prolonged viral replication and secondary gram-negative bacterial and 
fungal pneumonia and higher mortality; thus, corticosteroids should be avoided for specific 
treatment of influenza and associated ARDS.6 Concomitant bacterial community-acquired 
pneumonia, especially with Staphylococcus aureus (including methicillin-resistant S 
aureus), Streptococcus pneumoniae, or Streptococcus pyogenes, has been reported. 
Empirical broad-spectrum antimicrobial therapy should be initiated to cover these 
pathogens, with appropriate de-escalation of antibiotics when lower respiratory tract 
bacterial cultures return with definitive results.
ARDS and Nonrespiratory Organ Dysfunction
The cornerstone of modern ARDS care is low tidal volume lung protective ventilation and 
an open-lung approach with increased positive end-expiratory pressure/mean airway 
pressure. Despite standard ARDS management including conservative fluid strategy, 
H1N1pdm09-associated ARDS can be associated with severe hypoxemia and markedly 
abnormal lung compliance, with failure of routine ARDS management strategies in some 
patients. Thus, it is important for clinicians to consider early transfer of intubated patients 
with presumed H1N1pdm09 virus infection, especially if severe hypoxemia develops, to a 
regional referral center with experience providing more advanced “rescue” care, such as 
extracorporeal membrane oxygenation (ECMO).
Rescue strategies are approaches reserved for very critically ill patients to attempt to 
alleviate hypoxia and improve cardiopulmonary dynamics, although their effect on mortality 
is less clear. Examples include prone positioning, ECMO, neuromuscular blockade, inhaled 
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nitric oxide, and lung recruitment maneuvers. Prone positioning and ECMO appear to be 
associated with lower mortality in severe ARDS, although results are inconsistent.7 These 
strategies require considerable experience and resources, and the reported benefits are 
largely restricted to trials at referral centers.
Septic shock and refractory hypotension occur in approximately 30% of patients with 
H1N1pdm09-associated critical illness despite adequate fluid resuscitation, and high-dose 
vasopressors may be required.8 Acute kidney injury can occur and may require treatment 
with continuous renal replacement therapy due to concomitant hypotension from septic 
shock. Other less common severe complications, such as influenza-associated 
encephalopathy, encephalitis, myocarditis, and pericarditis, may be secondary to tissue 
injury from inflammation triggered by H1N1pdm09 virus infection of the respiratory tract. 
Additional complications include myositis and rhabdomyolysis with creatine phosphokinase 
elevations. In some severe ARDS cases, thromboembolic events (some fatal) have been 
documented, including primary pulmonary thrombi/emboli and deep venous thrombosis, and 
empirical systemic anticoagulation may be considered in high-risk patients. For patients 
with H1N1pdm09-associated ARDS and critical illness, prolonged ICU length of stay is 
common, clinical improvement is very slow, and some patients require weeks to months of 
mechanical ventilation and critical care support.
Influenza Testing and Antiviral Therapy
During influenza season, patients with respiratory failure or ARDS without an etiology 
should have lower respiratory tract specimens (endotracheal aspirate, bronchoalveolar lavage 
fluid) tested by reverse transcription-polymerase chain reaction (RT-PCR) for influenza viral 
RNA because upper respiratory tract specimens may be negative. Antigen detection tests 
(rapid influenza diagnostic tests, immunofluorescence assays) can produce false-negative 
results compared with RT-PCR.
There is no robust evidence from randomized clinical trials to guide antiviral therapy in 
critically ill patients with influenza. However, antiviral treatment, by reducing viral load, 
may ameliorate the inflammatory response and observational studies in critically ill 
influenza patients suggest some clinical benefit, especially if started early.9 To date, 
detection of oseltamivir-resistant H1N1pdm09 viruses has been uncommon.4 Therefore, 
empirical oseltamivir treatment is recommended as soon as possible before testing results 
are available.10 Standard-dose oseltamivir administered enterally in critically ill adults can 
be adequately absorbed. Higher oseltamivir dosing has been administered in hospitalized 
patients without benefit over standard dosing, but optimal dosing and duration of oseltamivir 
treatment in critically ill influenza patients are unknown. Because influenza viral replication 
may be prolonged, testing of serially collected lower respiratory tract specimens by RT-PCR 
may help inform length of therapy and duration of infection control measures. Severely 
immunosuppressed patients (eg, hemopoietic stem cell transplant recipients) are more likely 
to develop oseltamivir-resistant H1N1pdm09 virus infection due to prolonged viral 
replication.
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Patients for whom enteric administration is contraindicated or those with oseltamivir-
resistant virus infection may benefit from a parenteral neuraminidase inhibitor such as the 
investigational drug intravenous zanamivir. Antiviral dosing may need to be adjusted for 
patients requiring renal replacement therapy or ECMO. Failure to improve or clinical 
deterioration during oseltamivir treatment may be due to the progression of acute lung injury 
or other influenza-associated ARDS complications and is less likely due to emergence of 
oseltamivir resistance.
Strict adherence to influenza prevention and control measures can prevent health care-
associated influenza. All health care workers should receive influenza vaccination annually. 
Suspected and confirmed influenza patients should be isolated, and standard and droplet 
precautions should be implemented. For aerosol-generating procedures, fit-tested N95 
respirator or higher level of respiratory protection is indicated.
Future Directions
Key topics for clinical management of critically ill influenza patients include (1) how to 
better identify which patients will deteriorate; (2) what are optimal antiviral treatment 
strategies and end points; (3) what is the role of immunomodulators and other adjunctive 
therapies; and (4) what are the efficacy and effectiveness of ARDS rescue strategies? A 
better understanding of risk factors may be gleaned from ongoing observational studies and 
electronic health record data. However, optimal understanding requires prospective 
collection of high-quality clinical data and biologic specimens, including from randomized 
clinical trials conducted across ICU networks where care is standardized during epidemics 
and linked to public health surveillance data. National and international clinical research 
networks—including ISARIC (International Severe Acute Respiratory and Emerging 
Infection Consortium), InFACT (International Forum for Acute Care Trialists), USCIITG 
(US Critical Illness and Injury Trials Group), and PREPARE (Platform for European 
Preparedness Against Reemerging Epidemics)—are exploring a novel approach using an 
adaptive design that would permit testing of multiple therapies, including novel agents, 
enrollment across different regions and countries, random allocation rules that favor 
therapies that appear most efficacious, and recruitment during interpandemic periods. Such 
efforts can also inform clinical management of critically ill patients with infection caused by 
novel influenza A viruses (H5N1, H7N9) or other emerging viruses (eg, MERS-CoV) of 
global public health concern.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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